Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug product containing three active ingredients: - **Lidocaine** is a local anesthetic that works by blocking sodium channels in neuronal cell membranes, thereby inhibiting nerve impulse conduction and providing local numbness or anesthesia. - **Epinephrine** (also known as adrenaline) is a sympathomimetic agent that acts primarily on alpha and beta adrenergic receptors. When combined with lidocaine, it causes vasoconstriction at the site of injection, which reduces bleeding and prolongs the duration of anesthesia by slowing systemic absorption of lidocaine. - **Gadoterate meglumine** is a gadolinium-based contrast agent used to enhance visualization during magnetic resonance imaging (MRI). It works by altering the magnetic properties of nearby water molecules, increasing contrast between tissues for improved imaging[1][2][3][5][6]. This specific combination may be used in specialized interventional radiology or MRI-guided procedures where both local anesthesia and enhanced imaging are required. However, this exact triple combination does not appear to be marketed under any unique brand name; it represents an admixture prepared for procedural use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + epinephrine + gadoterate meglumine.